Edwards Lifesciences Corporation revised earnings guidance for the full year of 2022. For total Edwards, the company now expects full year 2022 sales of $5.35 to $5.55 billion. The company now expects full year adjusted EPS guidance at the bottom end of its original guidance range of $2.50 to $2.65, representing double-digit growth over 2021.